最新ニュース Nuvalent (NASDAQ:NUVL) 株価情報

Nuvalent

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

News

Movers

ACLS

AGIO

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？

直近1週間高パフォーマンスを示したのは、中型株

Nuvalent Inc

H.C. Wainwright initiated coverage of Nuvalent (NUVL) with a Buy rating and $110 price target Nuvalent is a clinical stage biotechnology company fo...

Nuvalent initiated with a Buy at H.C. Wainwright

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 12/31/2024, According to Top Analysts

Oppenheimer laid out five "aspirational" potential takeover targets in biotech heading into the annual JPMorgan Health Care Conference. "We need mo...

Opco lists five potential biotech targets into JPMorgan conference

Viking Therapeutics among potential buyout candidates: Oppenheimer

Nuvalent: A Logical Acquisition Target

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Nuvalent (NUVL – Research Report). The associated price target remains t...

Nuvalent's Strategic Progress and Clinical Advancements Justify Buy Rating

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nuvalent (NUVL – Research Report) and Danaher (DHR...

Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Danaher (DHR)

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Nuvalent (NUVL – Research Report), with a price target of $100.00...

Barclays Reaffirms Their Buy Rating on Nuvalent (NUVL)

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Nuvalent (NUVL – Research Report), retaining the price target of $110....

Nuvalent's Clinical Advancements and Strategic Growth Drive Buy Rating with $110 Price Target

ACLX

AMGN

ARQT

ARTV

AXSM

BPMC

CTOR

CTXR

GILD

JANX

NAMS

RCKT

VKTX

VSTM

Offerings

Press Releases

Nuvalent Announces Public Offering of Common Stock

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

Earnings

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nuvalent Appoints Grant Bogle to Board of Directors

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

NVCT

SMMT

ADMA Biologics

Alkermes

Alvotech

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biohaven

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Vaxcyte

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

HC Wainwright & Co.

BMO Capital

JP Morgan

Guggenheim

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？
<ol>
<li>Agios Pharmaceuticals Inc(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>)株は、企業が依存性輸血（TD）アルファまたはベータ地中海貧血の患者を対象にした臨床試験で<a href="https://www.benzinga.com//node/39141375">主要エンドポイントを達成</a>したと発表した後、先週29.13％急騰しました。 この発表を受けて、数人のアナリストが予測を<a href="https://www.benzinga.com/quote/agio/analyst-ratings">引き上げました</a>。</li>
<li>Verint Systems Inc。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>）の株価は、同社が先週火曜日に<a class="ticker" href="https://www.benzinga.com//node/39170267" target="_blank" rel="noreferrer noopener">予想を上回るQ1業績を発表し、強いFY25業績予測を示した</a>ことを受けて22.40％上昇しました。</li>
<li>Novavax Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>）の株は先週、米国食品医薬品局（FDA）の諮問委員会が新型コロナウイルスのJN.1系統向けの<a href="https://www.benzinga.com/general/biotech/24/06/39204978/novavax-stock-rallies-in-pre-market-as-company-plans-to-deliver-covid-19-vaccine-by-september">更新されたワクチンの推奨を可決した</a>と発表した後、21.54％上昇しました。</li>
<li>Nuvalent, Inc。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>）の株は20.52％上昇しました。</li>
<li>Neogen Corporation（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>）の株は19.25％上昇しました。</li>
<li>Twist Bioscience Corporation（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>）の株価は、Guggenheimが<a class="ticker" href="https://www.benzinga.com/quote/twst/analyst-ratings" target="_blank" rel="noreferrer noopener">株を「Buy」のレーティングでカバーし、53ドルの</a><a href="https://www.benzinga.com//node/39206468" target="_blank" rel="noreferrer noopener">株価ターゲットを発表した</a><a class="ticker" href="https://www.benzinga.com/quote/twst/analyst-ratings" target="_blank" rel="noreferrer noopener">ことで18.40％急騰しました。</a></li>
<li>Smartsheet Inc。（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>）の株価は、同社が予想を上回るQ1業績を発表し、<a href="https://www.benzinga.com//node/39195040" target="_blank" rel="noreferrer noopener">初めての1億5000万ドルの株買い戻しプログラムを発表した</a>ことで18.01％上昇しました。 これを受け、多くのアナリストが<a href="https://www.benzinga.com//node/39206468" target="_blank" rel="noreferrer noopener">株価ターゲットを変更しました</a>。</li>
<li>Halozyme Therapeutics, Inc。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>）の株価は14.03％急伸し、同社が<a href="https://www.benzinga.com//node/39211537" target="_blank" rel="noreferrer noopener">FY24業績見通しを引き上げた</a>ことが要因です。</li>
<li>Legend Biotech Corporation（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>）の<a href="https://www.benzinga.com/quote/legn/analyst-ratings" target="_blank" rel="noreferrer noopener">株価が13.93％上昇しました</a>。</li>
<li>Liberty Global Ltd。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYB#NASDAQ">LBTYB</a>）の株価は12.48％上昇しました。</li>
</ol>

Comments

Nuvalent

ニュース

最新ニュース Nuvalent (NASDAQ:NUVL) 株価情報

月曜日, 6 10, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル